贝伐珠单抗联合FOLFOX化疗方案对晚期结肠癌血清学指标的影响

Effect of Bevacizumab Combined with FOLFOX Chemotherapy Regimen on Serological Indexes of Patients with Advanced Colon Cancer

目的:探讨贝伐珠单抗联合FOLFOX化疗方案对晚期结肠癌患者血清学指标的影响。方法:选择2019年10月至2020年8月驻马店市中心医院收治的60例晚期结肠癌患者,随机数字表法分为两组,各30例。对照组采用FOLFOX化疗方案,观察组在对照组基础上加用贝伐珠单抗,连续使用5个周期。比较两组血清学指标[糖类抗原199(CA199)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)、环氧合酶2基因(COX-2)],并观察药物安全性。结果:两组治疗前血清学指标、用药后安全性比较,差异无统计学意义(P>0.05);两组治疗后CA199、CEA、VEGF、COX-2水平均降低,且观察组更低,差异有统计学意义(P<0.05)。结论:与单用FOLFOX化疗方案相比,在晚期结肠癌患者中加用贝伐珠单抗效果更佳,能够更好地控制病情,防止肿瘤进一步生长与转移,且不良反应并无增加。

Objective:To investigate the effect of bevacizumab combined with FOLFOX chemotherapy on the serum indexes of patients with advanced colon cancer.Methods:60 patients with advanced colon cancer treated in Zhumadian Central Hospital from October 2019 to August 2020 were randomly divided into two groups with 30 cases in each group.The control group was treated with FOLFOX chemotherapy,and the observation group was treated with bevacizumab on the basis of the control group for 5 consecutive cycles.The serological indexes[carbohydrate antigen 199(CA199),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),cyclooxygenase 2 gene(COX-2)]were compared between the two groups,and the drug safety was observed.Results:There was no statistically significant difference in the serum indexes and safety after treatment between the two groups(P>0.05);the levels of CA199,CEA,VEGF,and COX-2 in the two groups decreased after treatment,and the observation group was even lower,the difference was statistically significant(P<0.05).Conclusion:Compared with FOLFOX chemotherapy alone,bevacizumab is more effective in patients with advanced colon cancer,which can better control the disease,prevent further tumor growth and metastasis,and there is no increase in adverse reactions.